Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer

PURPOSE: This single-arm, open label Phase II study evaluated the safety and efficacy of taselisib (GDC-0032) plus fulvestrant in postmenopausal women with locally advanced or metastatic HER2-negative, hormone receptor (HR)-positive breast cancer. EXPERIMENTAL DESIGN: Patients received 6 mg oral tas...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Clin Cancer Res
Glavni autori: Dickler, Maura N., Saura, Cristina, Richards, Donald A., Krop, Ian E., Cervantes, Andrés, Bedard, Philippe L., Patel, Manish R., Pusztai, Lajos, Oliveira, Mafalda, Cardenas, Alison K., Cui, Na, Wilson, Timothy R., Stout, Thomas J., Wei, Michael C., Hsu, Jerry Y., Baselga, José
Format: Artigo
Jezik:Inglês
Izdano: 2018
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6139036/
https://ncbi.nlm.nih.gov/pubmed/29793946
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-0613
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items